Iris-claw phakic anterior chamber intraocular lens implantation for ultra-high myopia correction

Objective To evaluate the clinical efficacy and safety of the Iris-claw phakic anterior chamber intraocular lens implantation for ultra-high myopia. Methods To implant the Verisyse iris pinch-type phakic anterior chamber intraocular lens into 19 eyes of 10 patients with ultra-high myopia (with -15.50～-30.00 diopters), then to analyze pre and post operation eye refractive status,uncorrected visual acuity,corrected visual acuity, intraocular pressure,pupil speciation, corneal endothelial cell counts and intraocular lens location. Results 19 eyes got the best corrected vision when they were implanted. And most of the patients's best corrected acuity surpass the pre operation about 1～3 rows.(Pre operation the uncorrected visual acuity is 0.02～0.1; post operation the uncorrected visual acuity is 0.3～1.0) But the poor of the iris elasticity lead to 1 eye pupil's deformation and intraocular lens's anteversion,.then reducted after an other operation. Conclusions As refractive surgery, the iris pinch-type phakic anterior chamber intraocular lens implantation were used to cure ultra-high myopia, and showed its satisfactory clinical effects and some advantages: operative visual acuity recovered rapidly; stable diopter; few complications and good predictability, became the effective correct way to cure ultra-high myopia patients who is not suitable to receive a excimer laser corneal refractive surgery.